ArticleBlood2009
Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.
Article in Blood, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 30 citations in OpenAlex.
- Microwave ablation combined with dendritic cells enhances CD8Cancer immunology, immunotherapy : CII · 2026Article
- A rationally-engineered IL-2 improves the antitumor effect of anti-CD20 therapy.Oncoimmunology · 2020Article
- Memory CD8Seminars in immunology · 2020Review
- CD4Cancer science · 2020Article
- Article
- Article
- Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion.JCI insight · 2017Article
- PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8Frontiers in immunology · 2017Article
- Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling.Clinical cancer research : an official journal of the American Association for Cancer Research · 2015Article
- The inducible costimulator augments Tc17 cell responses to self and tumor tissue.Journal of immunology (Baltimore, Md. : 1950) · 2015Article
- A Perspective of Immunotherapy for Breast Cancer: Lessons Learned and Forward Directions for All Cancers.Breast cancer : basic and clinical research · 2015Review
- Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2014Article
- Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing.PloS one · 2014Article
- Skin-resident antigen-presenting cells: instruction manual for vaccine development.Frontiers in immunology · 2013Article
- Adoptive immunotherapy for cancer: harnessing the T cell response.Nature reviews. Immunology · 2012Review
- Determinants of successful CD8+ T-cell adoptive immunotherapy for large established tumors in mice.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Ten years of progress in vaccination against cancer: the need to counteract cancer evasion by dual targeting in future therapies.Cancer immunology, immunotherapy : CII · 2011Review
- Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice.Cancer immunology, immunotherapy : CII · 2011Article
- Autoimmune melanocyte destruction is required for robust CD8+ memory T cell responses to mouse melanoma.The Journal of clinical investigation · 2011Article
- Therapeutic cancer vaccines: are we there yet?Immunological reviews · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Naive and memory CD8(+) T cells can undergo programmed activation and expansion in response to a short T-cell receptor stimulus, but the extent to which in vitro programming can qualitatively substitute for an in vivo antigen stimulation remains unknown. We show that self-/tumor-reactive effector memory CD8(+) T cells (T(EM)) programmed in vitro either with peptide-pulsed antigen-presenting cells or plate-bound anti-CD3/anti-CD28 embark on a highly stereotyped response of in vivo clonal expansion and tumor destruction nearly identical to that of vaccine-stimulated T(EM) cells. This programmed response was associated with an interval of antigen-independent interferon-gamma (IFN-gamma) release that facilitated the dynamic expression of the major histocompatibility complex class I restriction element H-2D(b) on responding tumor cells, leading to recognition and subsequent tumor lysis. Delaying cell transfer for more than 24 hours after stimulation or infusion of cells deficient in IFN-gamma entirely abrogated the benefit of the programmed response, whereas transfer of cells unable to respond to IFN-gamma had no detriment to antitumor immunity. These findings extend the phenomenon of a programmable effector response to memory CD8(+) T cells and have major implications for the design of current adoptive-cell transfer trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.